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Abstract
Background:  Development of neural networks requires that synapses are formed, eliminated and
stabilized. At the neuromuscular junction (NMJ), agrin/MuSK signaling, by triggering downstream pathways,
causes clustering and phosphorylation of postsynaptic acetylcholine receptors (AChRs). Postnatally, AChR
aggregates are stabilized by molecular pathways that are poorly characterized. Gain or loss of function of
Src-family kinases (SFKs) disassembles AChR clusters at adult NMJs in vivo, whereas AChR aggregates
disperse rapidly upon withdrawal of agrin from cultured src-/-;fyn-/- myotubes. This suggests that a balance
between protein tyrosine phosphatases (PTPs) and protein tyrosine kinases (PTKs) such as those of the
Src-family may be essential in stabilizing clusters of AChRs.
Results: We have analyzed the role of PTPs in maintenance of AChR aggregates, by adding and then
withdrawing agrin from cultured myotubes in the presence of PTP or PTK inhibitors and quantitating
remaining AChR clusters. In wild-type myotubes, blocking PTPs with pervanadate caused enhanced
disassembly of AChR clusters after agrin withdrawal. When added at the time of agrin withdrawal, SFK
inhibitors destabilized AChR aggregates but concomitant addition of pervanadate rescued cluster stability.
Likewise in src-/-;fyn-/-  myotubes, in which agrin-induced AChR clusters form normally but rapidly
disintegrate after agrin withdrawal, pervanadate addition stabilized AChR clusters. The PTP SHP-2, known
to be enriched at the NMJ, associated and colocalized with MuSK, and agrin increased this interaction.
Specific SHP-2 knockdown by RNA interference reduced the stability of AChR clusters in wild-type
myotubes. Similarly, knockdown of SHP-2 in adult mouse soleus muscle by electroporation of RNA
interference constructs caused disassembly of pretzel-shaped AChR-rich areas in vivo. Finally, we found
that src-/-;fyn-/- myotubes contained elevated levels of SHP-2 protein.
Conclusion: Our data are the first to show that the fine balance between PTPs and SFKs is a key aspect
in stabilization of postsynaptic AChR clusters. One phosphatase that acts in this equilibrium is SHP-2. Thus,
PTPs such as SHP-2 stabilize AChR clusters under normal circumstances, but when these PTPs are not
balanced by SFKs, they render clusters unstable.
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Background
Neural networks are shaped through the formation, stabi-
lization and elimination of synapses that connect neurons
with their targets. The neuromuscular junction (NMJ), a
model synapse in the peripheral nervous system, forms by
the contact of motor neurons and muscle fibers. These
interactions lead to a polyinnervated synapse at birth, in
which acetylcholine receptors (AChRs) are clustered in a
flat, plaque-like postsynaptic membrane. In a postnatal
phase of elimination, NMJs mature and AChRs become
stabilized at the crests of postjunctional folds to form pret-
zel-shaped areas, while all but one axon withdraw in a
process in which adjacent AChRs are destabilized [1-3].
Mechanisms of stabilization of AChR clusters are thus
important for proper postnatal maturation of the NMJ,
which ultimately will allow for correct nerve-evoked mus-
cle contractibility.
The molecular processes that first form NMJs are well
known. Neural agrin, by activating the kinase MuSK, plays
a crucial role by triggering downstream signaling path-
ways that cause clustering and tyrosine phosphorylation
of AChRs, as reviewed recently [4,5]. Neural activity dis-
solves receptor clusters that are not protected by local
agrin deposition in the basal lamina, thereby shaping the
postsynaptic architecture [6]. In cultured myotubes, a
short pulse of agrin leads to long-lasting MuSK phospho-
rylation and normal AChR clustering much later, imply-
ing that, once activated, a balance of downstream protein
tyrosine kinases (PTKs) and protein tyrosine phos-
phatases (PTPs) keeps postsynaptic clustering mecha-
nisms activated [7].
Much less is known about the molecular pathways that
mature NMJs postnatally and stabilize adult pretzel-
shaped AChR clusters. Although MuSK is involved [8],
these pathways differ from those in NMJ induction [9,10].
Stability of AChR clusters can be modeled in cultured
myotubes, by adding and then removing agrin, and stud-
ying cluster dispersal in the withdrawal phase. Despite the
difference in time scale, this method reveals many paral-
lels to postnatal stabilization of the NMJ in vivo, which can
be assessed by electroporating interfering constructs into
mouse soleus muscle [8,11]. Thus, the protein complex
associated with utrophin including the components dys-
troglycan and dystrobrevin, and Src-family kinases (SFKs),
stabilize the postsynapse and AChR clusters both in vivo
and in cultured myotubes in vitro [11-16]. SFKs are acti-
vated by agrin [17], interact with AChRs [18,19], and
maintain AChR β subunit phosphorylation and interac-
tion of the receptor with its anchoring protein rapsyn
[11]. In cultured src-/-;fyn-/- myotubes, agrin or laminin
induce normal AChR clustering, but the clusters dissem-
ble rapidly within a few hours after withdrawal of these
factors [12,14]. SFKs act in a dual mechanism with choles-
terol-rich lipid microdomains related to lipid rafts, as
SFKs promote normal microdomain assembly, while the
microdomains allow SFKs to act upon postsynaptic pro-
teins [20]. In vivo, interfering with SFK function causes
postsynaptic disintegration of adult NMJs. Interestingly,
decreasing or increasing SFK activity through expression
of dominant-negative (kinase-dead) or constitutively
active Src both cause disassembly of AChRs aggregates in
vivo  [11]. This raises the possibility that balanced SFK
activity is important for postsynaptic stability and suggests
that PTPs may be involved in stabilization of AChR clus-
ters as well. One PTP known to be enriched at the NMJ is
the non-receptor phosphatase SHP-2 [21]. SHP-2 can
modulate agrin/MuSK signaling and neuregulin-regulated
AChR transcription [21,22], making it a good candidate
for postsynaptic signaling processes.
We have therefore analyzed the role of PTPs, especially
SHP-2, in the stabilization of AChR clusters, and their
interplay with SFKs. We find that phosphatases such as
SHP-2 stabilize AChR clusters after withdrawal of agrin
from cultured myotubes. SHP-2 is also necessary to stabi-
lize adult AChR pretzels at NMJs in mouse soleus muscle
in vivo. Interestingly, in src-/-;fyn-/- myotubes SHP-2 is over-
expressed, and blocking PTP activity restores AChR cluster
stability completely, showing that a fine balance of PTPs
with SFKs is crucial for maintaining AChR clusters.
Results
PTP inhibition by pervanadate reduces the stability of 
agrin-induced AChR clusters
To address the role of the activity of PTPs in the stabiliza-
tion of agrin-induced AChR clusters, we made use of the
potent PTP inhibitor sodium pervanadate [23,24] and
cultured C2C12 myotubes, in which AChRs were visual-
ized by treatment with fluorescent α-bungarotoxin (α-
BTX). PTP inhibition did not lead to any change in the
number of spontaneous AChR clusters observed per field
when compared to the untreated control (data not
shown). The stability of AChR clusters can be modeled in
cell culture by incubating C2C12 myotubes with agrin to
induce maximal clustering, followed by agrin withdrawal,
washing the cells, incubating them in agrin-free medium
for a number of hours, and counting clusters at the end of
this withdrawal period [7,11,12,14]. When pervanadate
was added at the time of agrin withdrawal, significantly
less AChR clusters were observed after a 16 h withdrawal
period than in controls lacking pervanadate (Figure 1).
These data show that block of PTP activity enhances the
disintegration of pre-existing agrin-induced AChR clusters
and that therefore, PTPs are required to stabilize clusters
of AChRs. This is a specific process operating in cells that
were previously exposed to agrin, since block of PTP activ-
ity as such does not alter the level of spontaneous AChR
clustering.BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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A balance of PTP and SFK activities stabilizes AChR 
clusters: the instability of AChR clusters in the absence of 
SFKs is rescued by pervanadate treatment
SFKs are key in stabilizing AChR clusters in vivo and in cul-
tured myotubes in vitro [11,12,14]. In src-/-;fyn-/- myotubes,
agrin induces normal AChR clustering, but the clusters
disassemble rapidly within few hours upon agrin with-
drawal [14]. We analyzed whether under these circum-
stances PTPs may also influence the stability of AChR
clusters. For this purpose we treated src-/-;fyn-/- myotubes
with agrin to induce maximal clustering, then withdrew
agrin and added pervanadate at the same time, for a with-
drawal period of 5 h. This pervanadate treatment pre-
vented AChR clusters from disappearing, such that
clusters remained completely stable during the with-
drawal period (Figure 2A, B). In sharp contrast, omitting
pervanadate led to disassembly of the agrin-induced clus-
ters down to spontaneous levels (Figure 2A, B). Thus,
block of PTP activity causes stabilization of AChR clusters
in the absence of Src and Fyn. This is a specific process that
only affects pre-existing agrin-induced clusters, because
pervanadate treatment alone did not alter the levels of
spontaneous clusters (data not shown). Moreover, when
added together with agrin, pervanadate did not affect the
extent of agrin-induced AChR clustering (data not
shown).
Src and Fyn are not the only members of this family of
kinases present in myotubes. A third member of the SFKs,
Yes, is present in muscle and upregulated in src-/-;fyn-/-
myotubes [14]. This led us to investigate whether the
observed destabilizing effect of PTPs was solely due to the
absence of Src and Fyn, or whether this effect would also
occur when all members of the SFKs in muscle were
blocked. We therefore made use of the specific inhibitor
PP2 to block SFKs in C2C12 myotubes [25]. We again
induced AChR clustering by agrin and then removed agrin
to analyze the effect on the stability of these AChR clus-
ters. We found that when added together with agrin, PP2
had no effect on the level of clustering induced by agrin
(data not shown), as has been previously observed [14].
However, upon removal of agrin, blocking SFKs with PP2
led to a two-fold decrease in the number of remaining
AChR clusters, almost down to spontaneous levels (Figure
2C, D). This instability was completely prevented when
PTPs were inhibited with pervanadate in the withdrawal
phase (Figure 2C, D). These data confirm those from src-/-
;fyn-/- myotubes and show, firstly, that SFK activity main-
tains the stability of AChR clusters in cultured wild-type
myotubes, similar to recent findings in muscle in vivo [11].
Secondly, PTPs destabilize AChR clusters in the absence of
SFK activity and could indeed be the key destabilizing fac-
tor for agrin-induced AChR clusters in the absence of
SFKs. Taken together, these data show that the stability of
agrin-induced AChR clusters following the withdrawal of
agrin requires a fine balance between the kinase activities
of SFKs and the phosphatase activities of PTPs.
Protein tyrosine phosphatase SHP-2 increasingly 
associates with MuSK upon agrin stimulation
We wanted to identify possible PTPs that play a role in sta-
bilization of AChR clusters. An example of how the activ-
ity of a PTP is required in positively controlling the actions
of a kinase is the regulation of Src activity by the SH2
domain-containing protein tyrosine phosphatase SHP-2
[26]. SHP-2 is enriched at neuromuscular synapses and
colocalizes with AChRs in vivo [21]. In cultured myotubes,
SHP-2 is a major PTP and can control the phosphoryla-
PTP inhibition by pervanadate reduces the stability of agrin- induced AChR clusters in C2C12 myotubes Figure 1
PTP inhibition by pervanadate reduces the stability 
of agrin-induced AChR clusters in C2C12 myotubes. 
(A) Myotubes were treated with agrin (1 nM) for 6–8 h, after 
which PTPs were blocked with 20 μM pervanadate at the 
point of agrin withdrawal (Agrin + Withdr. + PV) for a with-
drawal period of 16 h. In controls, cultures were left 
untreated (No Agrin), treated with agrin alone for 6–8 h 
(Agrin), or treated with agrin followed by withdrawal for 16 
h (Agrin + Withdr.). Cells were also treated with agrin for 6–
8 h + 16 h, and this produced the same amount of clusters as 
a 6–8 h agrin incubation (data not shown). AChRs were 
stained with rhodamine-α-BTX and analyzed by fluorescence 
microscopy. Scale bar, 40 μm. (B) The number of AChR clus-
ters per field was calculated using ImageJ software, using 
fixed intensity thresholds (150–255) and minimum area of 
100 pixels occupied by a cluster. The number of AChR clus-
ters per field (400× magnification) is shown as the percent-
age of clusters in agrin-treated cells (Agrin) (means ± SEM, N 
= 50 from four similar experiments). Phosphatase inhibition 
significantly decreases the number of pre-existing, agrin-
induced AChR clusters following agrin removal (** p < 0.01; 
two-tailed paired t test).BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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AChR cluster stability is rescued by PTP inhibition in src-/-;fyn-/- myotubes and PP2-treated C2C12 myotubes Figure 2
AChR cluster stability is rescued by PTP inhibition in src-/-;fyn-/- myotubes and PP2-treated C2C12 myotubes. (A) PTPs were blocked 
with 20 μM pervanadate in src-/-;fyn-/- myotube cultures at the point of agrin withdrawal for a period of 5 h (Agrin + Withdr. + PV), following agrin 
treatment for 16 h. As controls, myotubes were either left untreated (No Agrin), treated with agrin for 16 h (Agrin) or treated with agrin followed by 
withdrawal for 5 h (Agrin + Withdr.). AChRs were stained with rhodamine-α-BTX and analyzed by fluorescence microscopy. Scale bar, 40 μm. White 
arrowheads indicate AChR clusters. (B) The number of AChR clusters per myotube is shown as the percentage of clusters in agrin-treated src-/-;fyn-/- 
cells (Agrin) (means ± SEM; N = 15 from three similar experiments; **p < 0.01, ***p < 0.001 by two-tailed paired t test). Pervanadate restores cluster 
stability following agrin withdrawal in src-/-;fyn-/- myotubes. (C) The inhibitor PP2 was used to block SFK activity in C2C12 myotubes. Myotubes were 
treated with agrin for 6–8 h in the presence of 10 μM PP2 for the last 2 h (these 2 h were chosen to ensure that PP2 was effective at the point of agrin 
withdrawal). Agrin was removed and myotubes incubated with agrin-free medium in the presence of pervanadate and PP2 for 16 h (Agrin + Withdr. + 
PP2 + PV). In controls, cultures were treated with agrin followed by withdrawal for 16 h in the presence or absence of PP2 (PP2 was added 2 h before 
agrin removal) (Agrin + Withdr.; Agrin + Withdr. + PP2). AChRs were stained with rhodamine-α-BTX, analyzed by fluorescence microscopy. Scale 
bar, 40 μm. (D) The number of AChR clusters per field (400× magnification) was calculated, as described in Figure 1, as the percentage of agrin-treated 
C2C12 cells (Agrin) (not shown) (means ± SEM, N = 30 from three experiments). *** indicates significant difference to the other two bars (p < 0.001; 
two-tailed paired t test). Blocking SFKs with PP2 reduces the stability of pre-existing clusters in C2C12 myotubes, and pervanadate restores the stabil-
ity to normal levels.BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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tion level of MuSK and the extent of agrin-induced AChR
clustering [22]. SHP-2 is therefore a likely candidate PTP
for playing roles in the stabilization process of AChR clus-
ters.
We first determined whether SHP-2 is in a position to
affect cluster stabilization by testing its association with
MuSK. We treated C2C12 myotubes with agrin to induce
MuSK phosphorylation, following which we immunopre-
cipitated MuSK and probed for both MuSK and SHP-2.
We found that SHP-2 is co-immunoprecipitated together
with MuSK, also without agrin treatment, and that the
association between the two proteins increases 2.3-fold
following MuSK phosphorylation by agrin (Figure 3A).
Since SHP-2 is known to colocalize with AChRs and hence
presumably also with MuSK at NMJs [21], we investigated
this association between MuSK and SHP-2 further using a
heterologous cell system. We transfected COS cells with
myc-tagged MuSK and Flag-tagged SHP-2 constructs, and
visualized MuSK and SHP-2 in the transfected cells by
immunocytochemistry. As expected, being a ubiqui-
tously-expressed non-receptor PTP, SHP-2 was localized
throughout the whole of the cell, but also along mem-
brane ruffles on the plasma membrane (Figure 3B). On
the other hand, MuSK showed more of a membrane local-
ization, characteristic for a receptor tyrosine kinase (RTK).
SHP-2 and MuSK colocalized within these membrane ruf-
fles present along the plasma membrane (Figure 3B). They
however did not cause the relocalization of one another,
since singly-transfected COS cells also exhibited similar
distribution patterns of the expressed proteins (data not
shown).
From these results we can conclude that MuSK and SHP-2
colocalize in ruffles along the plasma membrane. They
also associate with one another, and SHP-2 increases its
association to MuSK upon MuSK activation by agrin, per-
haps through an interaction of the SH2 domains in SHP-
2 with MuSK phosphorylation sites. The association with
MuSK highlights that SHP-2 is in a position to affect AChR
cluster stability.
Knockdown of SHP-2 in myotubes by vector-driven shRNA 
specifically reduces SHP-2 protein levels
To address the role of SHP-2 in stabilization of AChR clus-
ters, we used a knockdown approach by RNA interference
(RNAi). We cloned three short-hairpin RNA (shRNA)
loops into the pSUPER.gfp vector and tested their efficacy
in downregulating SHP-2 expression in C2C12 myotubes.
We used shRNA loops generated against different regions
of the murine SHP-2 open-reading frame (ORF), based on
already published and successfully used siRNA or shRNA
sequences [27,28]. These constructs co-expressed EGFP,
allowing easy identification of the successfully transfected
myoblasts, and observation of the differentiation of these
myoblasts into mature myotubes. Transfection efficien-
cies at the myoblast level were 40–50%, which upon dif-
ferentiation and fusion led to close to 100% of the
myotubes expressing EGFP (see Figure 5A). By Western
blot analysis of C2C12 myotube lysates we probed for the
Protein tyrosine phosphatase SHP-2 increasingly associates  with MuSK upon agrin stimulation Figure 3
Protein tyrosine phosphatase SHP-2 increasingly 
associates with MuSK upon agrin stimulation. (A) 
C2C12 myotubes were treated with 0.5 nM agrin for 40 min. 
Following MuSK immunoprecipitation, immunoblotting for 
SHP-2 and MuSK was carried out, followed by reprobing for 
phosphorylation of MuSK. Levels of SHP-2 co-precipitated 
with MuSK were quantitated (normalized for the amount of 
precipitated MuSK) as percentage of No Agrin control. Co-
immunoprecipitation of SHP-2 with MuSK indicates its spe-
cific association with MuSK, which increases significantly 
upon agrin-induced MuSK phosphorylation (means ± SEM, 
from seven experiments; * p < 0.05; two-tailed unpaired t 
test). As a control, the MuSK antibody was omitted in the 
immunoprecipitation, leading to no substantial signal in the 
Western blots (not shown). (B)COS cells were co-trans-
fected with SHP-2-Flag and MuSK-myc constructs. Cells 
were then fixed and stained with anti-Flag/Alexa488 and anti-
myc/Alexa546 antibodies. SHP-2 localizes throughout the 
whole of the cytoplasm, while MuSK localization is concen-
trated along the plasma membrane. White arrowheads in the 
overlay indicate a colocalization of MuSK and SHP-2 along 
membrane ruffles on the plasma membrane. Scale bar, 40 
μm.BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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Gene-specific targeting of SHP-2 in C2C12 myotubes through vector-driven shRNA specifically knocks down SHP-2 protein Figure 4
Gene-specific targeting of SHP-2 in C2C12 myotubes through vector-driven shRNA specifically knocks down 
SHP-2 protein. (A) C2C12 myotubes were transfected with pSUPER.shSHP2 construct targeting a specific region of the 
murine SHP-2 ORF. No transfection (Untransf.) or pSUPER vector only (pSUPER) transfected myotubes served as controls. 
Western blot analysis of SHP-2 levels revealed that pSUPER.shSHP2 knocked down > 60% of endogenous SHP-2. SHP-2 levels 
were quantitated by densitometric scanning and are shown as % of pSUPER vector only transfected myotubes (means ± SEM, 
from eight experiments). *** indicates a significant difference to the other bars (p < 0.0001; two-tailed unpaired t test). (B) The 
effect of SHP-2 gene targeting on levels of several postsynaptic proteins and functional surface AChRs was analyzed by pSU-
PER.shSHP2 transfection followed by Western blot analysis or radioligand binding assays (125I-α-BTX binding to intact C2C12 
myotubes). This revealed that SHP-2 knockdown does not significantly influence the levels of MuSK, Src, rapsyn and β-dystro-
glycan. Protein levels were calculated and shown as % of respective pSUPER vector only transfected myotubes (means ± SEM, 
from eight experiments). Equal amounts of overall protein were loaded on the gels. Similarly, 125I-α-BTX binding to surface 
AChRs in intact C2C12 myotubes shows that following SHP-2 knockdown there is no significant effect on the surface levels of 
AChRs, when compared to radioligand binding on control transfected myotubes.BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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effective suppression of endogenous SHP-2 protein. One
of the three constructs, termed pSUPER.shSHP2, led to a
strong (> 60%) reduction of endogenous SHP-2 protein
levels when compared to control transfected myotubes
(pSUPER vector only; Figure 4A). We therefore proceeded
to analyze the effect of SHP-2 downregulation on other
postsynaptic proteins. In immunoblots, levels of other
postsynaptic proteins such as MuSK, Src, rapsyn and β-
dystroglycan were not affected by SHP-2 knockdown (Fig-
ure 4B). Using radioligand binding of 125I-α-BTX we
probed functional surface AChRs following transfection
with pSUPER.shSHP2 and observed no significant effect
(Figure 4B). pSUPER.shSHP2  thus allows specific and
strong knockdown of SHP-2 without interfering with
other muscle proteins.
SHP-2 is required for stabilization of AChR clusters in 
cultured myotubes
To study the role of SHP-2 for AChR cluster stability, we
used C2C12 myotubes and suppressed SHP-2 by shRNA
as described above. We incubated the cells with agrin to
induce maximal clustering and withdrew the agrin to
assess the stability of the clusters. In both control cells
(pSUPER) and after SHP-2 knockdown (pSUPER.shSHP2),
spontaneous AChR aggregates were present and agrin
induced strong clustering of the receptors (Figure 5A),
similar to a recent report [22]. After withdrawal of agrin
for 8 h, few clusters remained in pSUPER.shSHP2-trans-
fected cells whereas more clusters were present in pSU-
PER-treated cells (Figure 5A).
To quantitate the effect of SHP-2 knockdown on the sta-
bility of agrin-induced AChR clusters, we normalized the
number of AChR clusters following agrin withdrawal
("Agrin + Withdr.") to the number of clusters that were
induced by agrin ("Agrin") in pSUPER.shSHP2- and pSU-
PER-transfected cells. The result shows that there is a sig-
nificant decrease in the stability of AChR clusters
following agrin withdrawal when SHP-2 expression is
knocked down by shRNA (Figure 5B). These data illustrate
that SHP-2 is required for optimal stabilization of AChR
clusters in cultured myotubes.
Upon knockdown of SHP-2 in C2C12 myotubes, AChR clusters are less stable Figure 5
Upon knockdown of SHP-2 in C2C12 myotubes, AChR clusters are less stable. (A) pSUPER-, and pSUPER.shSHP2-
transfected C2C12 myotubes were either left untreated (No Agrin), treated with agrin for 16 h (Agrin), or treated with agrin 
(16 h) followed by withdrawal of agrin for 8 h (Agrin+Withdr.). AChRs were identified by rhodamine-α-BTX staining and cells 
were analyzed by fluorescence microscopy. Scale bar, 40 μm. Transfected myotubes expressing EGFP indicated that transfec-
tion efficiency at the myotube level approached 100%. The data show that agrin induces AChR clustering both in pSUPER- and 
pSUPER.shSHP2-transfected myotubes. After the withdrawal phase, less clusters remain in the case of SHP-2 knockdown when 
compared to the control. (B) The stability of clusters was quantitated by setting the number of AChR clusters in agrin-treated 
myotubes (Agrin) to 100%, both for pSUPER-, and pSUPER.shSHP2-transfected myotubes. Clusters after the withdrawal period 
(Agrin + Withdr.) were then calculated accordingly. The absence of SHP-2 renders AChR clusters significantly less stable when 
compared to control transfected myotubes (means ± SEM, N = 30 from four similar experiments; *p < 0.05; two-tailed 
unpaired t test).BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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Electroporation of SHP-2 shRNA construct into soleus muscle of adult mice leads to disassembly of NMJs Figure 6
Electroporation of SHP-2 shRNA construct into soleus muscle of adult mice leads to disassembly of NMJs. 
Adult mice soleus muscles were electroporated in vivo with a mixture of pSUPER.shSHP2 and NLS-GFP constructs (A, C), or 
pSUPER vector and NLS-GFP as control (B, D). After six weeks muscles were dissected, whole mounts of fibers prepared and 
stained with rhodamine-α-BTX and a mixture of neurofilament and synaptophysin antibodies followed by Cy5 secondary anti-
body. NMJs were analyzed by confocal microscopy, whereby successfully electroporated muscle fibers were identified by the 
expression of NLS-GFP in myonuclei. (A) Expression of pSUPER.shSHP2 results in NMJ disassembly in GFP-positive myofibers 
(closed arrowhead). NMJs of GFP-negative fibers remain intact (open arrowheads). (B) Expression of control pSUPER vector 
and NLS-GFP has no effect on the NMJs. A three-dimensional reconstruction of a confocal image of a muscle electroporated 
with pSUPER.shSHP2 and NLS-GFP (C), or control pSUPER vector and NLS-GFP (D) shows details of the NMJs. (C) A 3D view 
from inside the muscle illustrates that expression of SHP-2 shRNA leads to disassembly of the NMJ, loss of the usual morphol-
ogy and pretzel shape, and a resulting fragmented appearance of the NMJ, with the nerve becoming visible through the pretzel 
remnants. (D) In control electroporated muscle fibers, GFP-positive synaptic nuclei are located below the intact pretzel-shaped 
accumulations of AChRs and no nerve is visible through the pretzel. (E) The number of intact and disassembled NMJs is shown 
for control (pSUPER) vector and pSUPER.shSHP2 electroporated muscle fibers, as percentage of the total number of NMJs ana-
lyzed (total of 25 endplates from 3 mice for pSUPER and 15 endplates from 5 mice for pSUPER.shSHP2). Only endplates with 
synapse-associated nuclei expressing NLS-GFP were analyzed. Scale bars, 30 μm in A, B; 10 μm in C, D.BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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Requirement of SHP-2 for stabilization of postsynaptic 
AChR pretzels at the NMJ in vivo
To address the role of SHP-2 in stabilization of postsynap-
tic AChRs at the NMJ in vivo, we used RNA interference in
soleus muscles of adult mice as described earlier [8,11].
The shRNA construct pSUPER.shSHP2, together with a
construct expressing GFP containing a nuclear localiza-
tion signal (NLS-GFP), was introduced into adult soleus
muscle by electroporation. After 6 weeks, muscles were
dissected, stained as whole mount preparations with
rhodamine-α-BTX and antibodies against neurofilament
and synaptophysin, and analyzed by confocal microscopy
including 3D reconstruction.
The in vivo expression of pSUPER.shSHP2 led to the disas-
sembly of adult pretzel-shaped AChR clusters (Figure 6A,
closed arrowhead). This was in sharp contrast to the intact
AChR pretzel structures observed at NMJs of neighboring
GFP-negative myofibers (Figure 6A, open arrowheads)
and of myofibers of mice electroporated with control pSU-
PER vector and NLS-GFP (Figure 6B).
Disassembled NMJs of myofibers expressing SHP-2
shRNA lost their typical pretzel morphology and were
fragmented (example in Figure 6C) and sometimes alto-
gether widened in appearance (example in Figure 6A). In
addition, the synapse-associated myonuclei were some-
times no longer tightly packed subsynaptically but associ-
ated more loosely with the disassembled AChR pretzel
(Figure 6C). In contrast, in myofibers electroporated with
control pSUPER vector, the nerve was hardly visible from
inside the muscle and synaptic nuclei were clustered just
beneath the AChR pretzels (Figure 6D).
A quantitative assessment was made following the criteria
described earlier [11](see also Method section), by analyz-
ing many NMJs from several mice, for both pSU-
PER.shSHP2 and pSUPER control vector. In the control,
almost all NMJs scored as intact, but in myofibers where
SHP-2 was suppressed, only a minority (less than 25%) of
all NMJs analyzed was intact and most synapses scored as
disassembled. These data show that SHP-2 is required for
maintenance of the adult postsynaptic apparatus of the
NMJ  in vivo including typical pretzel-shaped AChR
domains and synaptic myonuclei. These results are very
similar to the role of SHP-2 in stabilization of agrin-
induced AChR clusters in myotubes in vitro.
Elevated levels of SHP-2 in the absence of Src and Fyn
We have observed similar destabilizing effects on AChR
clusters in C2C12 myotubes upon PTP inhibition by per-
vanadate, and upon knockdown of SHP-2 by shRNA (Fig-
ures 1 and 5). This instability is also present in the absence
of Src and Fyn [14], or upon blocking SFKs with the inhib-
itor PP2, and is rescued completely by inhibition of phos-
phatase activity by pervanadate (Figure 2). These
observations lead to the conclusion that it is the balance
between PTK and PTP activity that regulates the stability of
AChR clusters in myotubes. For this reason we sought to
compare the levels of SHP-2 between src-/-;fyn-/- myotubes
and wild-type myotubes. We carried out Western blot
analysis of myotube lysates, and found that SHP-2 levels
are 3-fold higher in myotubes lacking Src and Fyn com-
pared to wild-type myotubes (Figure 7). This finding sug-
gests that these high levels of SHP-2 may cause cluster
destabilization and further strengthens our proposal that
a crucial aspect for AChR cluster stabilization is the bal-
ance between Src and Fyn, and PTPs such as SHP-2.
Elevated protein levels of SHP-2 in the absence of Src and  Fyn Figure 7
Elevated protein levels of SHP-2 in the absence of 
Src and Fyn. Western blot analysis of total SHP-2 protein 
levels in wild-type versus src-/-;fyn-/- myotubes reveals that in 
the absence of Src and Fyn there is a >3-fold increase in the 
protein levels of SHP-2. SHP-2 levels are shown for both 
wild-type and src-/-;fyn-/- myotubes; equal amounts of cellular 
protein were loaded on the gel. In the quantitation, SHP-2 
levels are normalized for the level of AChR β subunit (*p < 
0.05; two-tailed unpaired t test).BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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Discussion
We have analyzed the role of PTPs in the stabilization of
AChR clusters and report that PTPs are required for cluster
maintenance and that the fine balance between PTPs and
SFKs is a key aspect in this process. On one hand, block of
PTPs by pervanadate or knockdown of SHP-2 in wild-type
myotubes both rendered agrin-induced clusters less sta-
ble. In vivo, SHP-2 knockdown in muscle caused disassem-
bly of adult pretzel-shaped AChR-rich areas at NMJs. On
the other hand, pervanadate restored the defective stabil-
ity of clusters in myotubes lacking SFK activity, and src-/-
;fyn-/- myotubes had elevated levels of SHP-2. Thus, PTPs
such as SHP-2 stabilize AChR clusters under normal cir-
cumstances, but when these PTPs are not balanced by
SFKs, they render clusters unstable.
PTPs such as SHP-2 stabilize AChR clusters
We used two approaches to illustrate the role of PTPs in
the maintenance of AChR clusters: inhibiting the activity
of all PTPs by pervanadate, and testing the role of a candi-
date PTP, SHP-2. The stability of AChR clusters was mod-
eled in cell culture, by adding and then removing agrin,
and pervanadate was added at the point of agrin with-
drawal to specifically test its effect on the maintenance of
pre-existing agrin-induced clusters. The withdrawal and
washing procedure removes the vast majority of agrin
from cells, such that signaling processes in the myotubes
during the withdrawal phase do not reflect the activity of
extracellular agrin but ongoing processes within the myo-
tubes [7]. When agrin is withdrawn from wild-type myo-
tubes, AChR clusters slowly disintegrate over the course of
several hours [29]. Block of PTPs by pervanadate acceler-
ated the decay of clusters, showing that PTP activity is a
requirement for optimal AChR cluster stability. This was a
specific process, since pervanadate as such did not alter
levels of spontaneous AChR clustering. Rather, following
an agrin stimulation to produce maximal aggregates, PTPs
act to fully maintain these clusters.
PTPs exist in many families, as receptor tyrosine phos-
phatases or cytosolic non-receptor phosphatases, similar
to kinase families. While several PTPs could share the
function of maintaining AChR clusters, we identified
SHP-2 as one PTP that plays such a role. SHP-2 has previ-
ously been put into the context of the NMJ as a regulator
of AChR synthesis and MuSK activity [21], and we first fur-
ther verified whether SHP-2 is located to play a postsynap-
tic role. We found SHP-2 to associate with MuSK, and this
association to be increased (2.3-fold) by an agrin treat-
ment that caused heavy MuSK tyrosine phosphorylation.
In COS cells, MuSK and SHP-2 showed colocalization in
membrane ruffles at the plasma membrane, implying that
they can interact with each other independently of mus-
cle-specific linker proteins. These data show that SHP-2,
by increasingly interacting with MuSK, is positioned to
control postsynaptic stability of AChR clusters.
We determined the role of SHP-2 in the stabilization of
AChR clusters by an RNAi strategy, using vector-driven
shRNA and short-hairpin loops that were previously used
to knock down SHP-2 [27,28]. One of the shRNA con-
structs tested (pSUPER.shSHP2) was effective in myotubes
when using an efficient transfection protocol that allowed
its expression in nearly 100% of myotubes. pSU-
PER.shSHP2 massively reduced protein amounts of SHP-2
without significantly interfering with other postsynaptic
proteins such as MuSK, Src, rapsyn and β-dystroglycan or
with levels of functional AChR at the cell surface. This spe-
cificity in knockdown allowed the study of the role of
SHP-2 in AChR cluster stability.
In the absence of normal SHP-2 levels, spontaneous AChR
aggregates were present and AChR clusters were induced
by agrin, but the stability of these clusters was reduced
compared to controls, showing that, similar to the results
described above with pervanadate, SHP-2 stabilizes AChR
clusters. SHP-2 was also important at NMJs in vivo,
because electroporation of pSUPER.shSHP2  into adult
mouse soleus muscle led to disassembly of the postsyn-
apse: pretzel-shaped AChR-rich areas became fragmented
and some lost their overall pretzel outline, and sometimes
myonuclei were no longer packed subsynaptically but
more loosely associated with fragmented AChR cluster
remnants. Taken together, our data show that SHP-2 is a
PTP that, perhaps together with other PTPs, contributes to
the maintenance of AChR clusters at NMJs in vivo and in
cultured myotubes in vitro.
Upon knockdown of SHP-2, fragments of AChR clusters
were visible at NMJs but not in cultured myotubes from
which agrin had been withdrawn. In myotubes, cluster
disappearance appears as a statistical process whereby
some clusters still exist while others have vanished and are
outside the detectable ranges used in our method. This
could point towards differences in cluster dynamics
between our in vitro and in vivo systems. Such differences
could result from one or more of several possibilities: at
NMJs, the turnover of AChRs is much slower and the sub-
synaptic cytoskeleton more elaborate, presumably immo-
bilizing the AChR in a stronger fashion; cultured
myotubes lack innervation and the continuous presence
of basal lamina-anchored agrin as seen in vivo; and the
timing of AChR cluster disassembly is different as indi-
cated by the different time scale of our in vivo vs. in vitro
analysis. However, equally likely is the possibility that
upon SHP-2 knockdown and agrin withdrawal, AChR
cluster fragments do exist in cultured myotubes but can-
not be visualized due to low intensity; in comparison the
density of AChRs in pretzels is much higher in vivo. Fur-BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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thermore, fragments of AChR pretzels may completely
disappear from pSUPER.shSHP2-expressing myofibers
after prolongated times.
There are several possibilities of how SHP-2 could act to
maintain clusters. The agrin-induced increase in MuSK-
SHP-2 interaction is very similar to SHP-2 association
with tyrosine phosphorylated DOK1, a member of insulin
receptor substrate protein family that binds β3. Associa-
tion with DOK1 also occurs under basal conditions, and
upon stimulation of DOK1 by insulin-like growth factor I
(IGI-I), SHP-2-DOK1 association increases 2.7-fold. This
association is important for DOK1 to present SHP-2 to
downstream SHPS-1 [30,31]. In a similar fashion, SHP-2
associates, via its SH2 domains, to other RTKs including
the platelet-derived growth factor (PDGF) and epidermal
growth factor (EGF) receptors [32]. In SHP-2, the engage-
ment of the N-SH2 domain is required for its activation
[33,34]. By inference, in our case, SHP-2 recruitment to
tyrosine phosphorylated MuSK may allow for proper
SHP-2 localization at the muscle membrane, and at sites
where its phosphatase activity would be required in post-
synaptic stabilization. Possible downstream targets of
recruited SHP-2 could be MuSK itself, allowing fine-tun-
ing of MuSK phosphorylation levels in a feedback mecha-
nism [22] or SFKs. SHP-2 is known to interact [35] and
positively regulate Src activity, either directly or through
intermediate proteins such as PAG and Csk [26,35,36].
SHP-2 could also associate with and dephosphorylate the
AChR as proposed earlier [37]; the AChR is known to
undergo dephosphorylation in myotubes, since pervana-
date treatment rapidly causes strong AChR β phosphoryla-
tion [23].
The balance does the trick: upon lack of balance by SFKs, 
PTPs destabilize AChR clusters
We unraveled the mechanism by which PTPs such as SHP-
2 act in stabilizing postsynaptic AChR clusters by testing
their interplay with SFKs. We used two models: src-/-;fyn-/-
myotubes, and wild-type (C2C12) myotubes treated with
the specific inhibitor PP2. In both situations, agrin
induced normal AChR clusters, but upon agrin with-
drawal these clusters disintegrated more rapidly than in
the parallel controls. Importantly, in both src-/-;fyn-/- myo-
tubes and PP2-treated C2C12 myotubes, blocking PTPs
with pervanadate after agrin induction restored stability of
the pre-existing agrin-induced clusters. This stabilization
was a specific process by several criteria: pervanadate did
not alter levels of spontaneous clusters; the stability, not
the formation of clusters was affected by having less SFKs;
and when added together with agrin, pervanadate did not
affect formation of AChR clusters in src-/-;fyn-/- myotubes.
Interestingly, src-/-;fyn-/- myotubes were found to have sub-
stantially elevated levels of SHP-2 protein. The elevated
amounts may be the result of changes in SHP-2 synthesis,
turnover or degradation, and the amounts may be an
attempt of src-/-;fyn-/- myotubes to produce normal SFK
activity, because SHP-2 is known to activate SFKs, at least
in other cells [26,35,36]. Along the same lines, levels of
the SFK member Yes are upregulated in src-/-;fyn-/- myo-
tubes [13].
Collectively, our data show that in the absence of normal
SFK activity, PTPs no longer act to stabilize AChR clusters
(as is normally the case). Rather, PTPs, when not counter-
balanced by SFKs, destabilize the clusters, and blocking
PTP activity restores cluster stability. In a related mecha-
nism, agrin activates PTKs as well as PTPs in Xenopus mus-
cle cells, and this allows formation of new AChR clusters
but at the same time causes disassembly of pre-existing
spontaneous AChR hotspots. Hotspot disassembly is
blocked by pervanadate, implying that agrin-activated
PTPs disassemble AChR clusters when they are not pro-
tected by local agrin-activated PTKs [22].
Our findings strengthen the proposal that it is the balance
between PTKs such as SFKs and PTPs such as SHP-2,
which controls AChR cluster stability. In src-/-;fyn-/- myo-
tubes, elevated SHP-2 levels could be causing the instabil-
ity of AChR clusters. Using the inhibitor pervanadate on
these myotubes could bring down the phosphatase activ-
ity, normalizing the PTP-PTK balance in the system, and
allowing for more stable AChR clusters. On the other
Model for a balance between PTPs such as SHP-2 and kinases  such as SFKs, which stabilizes postsynaptic AChR clusters Figure 8
Model for a balance between PTPs such as SHP-2 
and kinases such as SFKs, which stabilizes postsynap-
tic AChR clusters. Process A, stabilization: MuSK-bound 
and activated SHP-2 could activate SFKs, leading to AChR β 
phosphorylation, stable AChR-rapsyn (rap) interaction and 
phosphorylation of cytoskeletal regulators (e.g. actin-control-
ling proteins such as the SFK-substrates cortactin, 
p190RhoGAP or WASp). Process B, destabilization: SHP-2 
may dephosphorylate AChR β and the cytoskeletal regula-
tors. A balance between A and B keeps clusters intact. UGC, 
utrophin-glycoprotein complex: an array of proteins that sta-
bilize the postsynaptic apparatus. Members of this complex 
interact with rapsyn (β-dystroglycan) and actin (utrophin).BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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hand, in wild-type myotubes phosphatase inhibition by
pervanadate reduces the phosphatase activity below nor-
mal levels, tipping the balance towards increased PTK
activity, and leading to a destabilization of the system and
consequently of AChR clusters.
The balance of SFKs and SHP-2 also plays in vivo: very sim-
ilar to our present findings on SHP-2, it was recently
shown, using the same electroporation technique, that a
decrease or increase in SFK activity causes disassembly of
postsynaptic pretzel-shaped AChR clusters and often dis-
placement of subsynaptic myonuclei [11]. Thus interfer-
ing with SFK activity produces the same effect as reducing
SHP-2 function at NMJs in vivo.
Our results describe a "phosphostat", which is required to
keep AChR clusters optimally stable, but what could be
the effector machinery that translates this phosphostat
into postsynaptic stability? Most likely it is not just a clas-
sic simple mechanism where PTKs phosphorylate targets
whereas PTPs dephosphorylate them. Rather, it appears to
be a combination of common phosphorylation substrates
and mutual control of activity of PTKs and PTPs. Since
SHP-2 positively controls the activity of Src kinase [26],
block of SHP-2 would result in less Src activity, leading to
unstable AChR clusters. This may indeed be part of the sit-
uation in our C2C12 myotubes and at NMJs in vivo, where
PTP block or SHP-2 knockdown destabilizes AChR clus-
ters. On the other hand, AChR β subunit phosphorylation
is a factor for efficient receptor clustering and cytoskeletal
anchorage, and the AChR is dephosphorylated by PTPs, as
shown by its overphosphorylation due to pervanadate
treatment [23,38], also in our cultures (data not shown).
With this in mind, blocking PTPs would be expected to
lead to more stable AChR phosphorylation and thus to
more stable clusters. However, the fact that pervanadate
treatment increases AChR phosphorylation but destabi-
lizes AChR clusters shows that phosphorylation of the
receptor itself is not sufficient to keep clusters stable.
Rather, other processes govern the stability of AChR aggre-
gates, and SHP-2-mediated SFK activation governing acti-
vation of downstream substrates is one possibility in vitro
and in vivo.
In the absence of SFKs, unbalanced PTP activity leads to
dephosphorylation of AChRs, as shown in the agrin with-
drawal phase in src-/-;fyn-/- myotubes [11], and most likely
of other downstream substrates such as cytoskeletal
organizers. Accordingly, the strength of the overall
cytoskeletal link of AChRs is reduced in src-/-;fyn-/- myo-
tubes [11]. From studies on non-muscle cells, cortactin,
p190RhoGAP and WASp are known direct substrates of
SFKs and involved, via direct or indirect action upon the
Arp2/3 complex, in the dynamics of actin filaments
[39,40]. Actin reorganization, in turn, and the action of
Rac and Cdc42 (which can regulate cortactin and WASp,
respectively) are important in clustering of AChRs [41-
43]. Dephosphorylation of such regulators in the absence
of SFKs could be a further reason for postsynaptic instabil-
ity [11], and blocking PTPs could restore the activity of the
regulators to normal operating levels, thereby stabilizing
clusters.
These considerations lead to a model in which, in the sta-
bilization phase of postsynaptic AChR clusters, PTPs such
as SHP-2 associate with MuSK. Besides fine-tuning MuSK
dephosphorylation, PTPs keep, indirectly or directly, SFKs
activated (Figure 8, process A). This activity maintains
AChR β phosphorylation, AChR-rapsyn interaction [11]
and may maintain phosphorylation of critical down-
stream cytoskeletal regulators at operating levels. In paral-
lel, PTPs such as SHP-2 dephosphorylate AChRs and the
downstream regulators (Figure 8, process B). Under nor-
mal circumstances the balance of process A and B leads to
a certain level of AChR and substrate phosphorylation,
keeping clusters stable. Upon block of PTPs, SFK activity is
compromised and clusters unstable. In the absence of
SFKs, process B dominates, destabilizing clusters, but PTP
block rescues stability.
Thus the effector pathway that operates between this PTP-
PTK phosphostat and postsynaptic stabilization through
AChR phosphorylation and cytoskeletal intermediates
could be complex and awaits further investigation.
Another level of complexity lies in the possible compen-
sation between different PTPs or between PTP families,
and this could explain why upon inactivation of the SHP-
2 gene in muscle, no clear effect was seen at NMJs in vivo
[44].
Conclusion
In summary, our data show that PTPs such as SHP-2 sta-
bilize postsynaptic AChR clusters and that the fine bal-
ance between PTPs and SFKs is a key aspect in this process.
The data are the first, to our knowledge, to demonstrate a
role for a tyrosine phosphatase in postsynaptic stabiliza-
tion of a synapse in the nervous system in vivo. Previous
reports concentrated on the role of PTPs in neurotransmit-
ter receptor trafficking underlying synaptic plasticity [45],
identified presynaptic PTP actions [46,47], or were lim-
ited to in vitro cultured neurons [48].
In our experiments, pharmacological inhibition of PTPs
or knockdown of SHP-2 render AChR clusters less stable,
whereas PTP inhibition restores the defective stability of
clusters in myotubes lacking SFK activity. In addition, src-
/-;fyn-/-  myotubes, which have unstable AChR clusters,
show elevated levels of SHP-2 protein. Thus, under nor-
mal circumstances PTPs such as SHP-2 stabilize AChRBMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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clusters; but when these PTPs they are not balanced by
SFKs, then they destabilize clusters.
While the crucial role of a balance between PTPs such as
SHP-2 and kinases such as SFKs for AChR cluster mainte-
nance is clear from the present study, the underlying
cytoskeletal pathways and downstream targets await fur-
ther investigation.
Methods
Expression of agrin and cell culture
The agrin used in this paper is a soluble neural agrin con-
struct (C-Ag12,4,8) [49] and was produced in COS cells as
previously described [50]. C-Ag12,4,8 lacks the N-terminal
half of agrin including the laminin binding site but can
interact with dystroglycan, activate MuSK and induce clus-
tering of postsynaptic proteins in cultured myotubes, as
full-length agrin does [51,52]. Reagents for cell culture
were purchased from Invitrogen AG (Basel, Switzerland).
C2C12 mouse muscle cells were propagated as myoblasts
on 3.5 or 6 cm (Corning), and 10 or 15 cm plastic dishes
(Nunc) in Dulbecco's modified Eagle's medium (DMEM)
with 4.5 g/l D-glucose and pyruvate, supplemented with
20% fetal bovine serum, 0.5% chick embryo extract, 2
mM glutamine and penicillin/streptomycin. After reach-
ing 90–100% confluence, cells were shifted to fusion
medium containing DMEM, 5% horse serum and 2 mM
glutamine and penicillin/streptomycin. Fusion of myob-
lasts to generate myotubes was evident after 1 day. By 2–
3 days, contracting myotubes were usually observed, and
cells were used for experiments [50]. src-/-;fyn-/- myoblasts
(clone DM15), and the corresponding wild-type myob-
lasts (SW10) were grown in 6 and 10 cm plastic plates
(Nunc) in DM growth medium and switched to DM
fusion medium to form myotubes as previously described
[11,14].
Inhibitors
Sodium pervanadate was prepared as previously described
[23,53]. One part of 500 mM hydrogen peroxide was
added to 50 parts of 10 mM sodium orthovanadate
(Sigma) (pre-boiled at 100°C for 10 minutes) in modi-
fied Tyrodes solution (145 mM NaCl, 5 mM KCl, 5.5 mM
glucose, 40 μM CaCl2, 1 mM MgCl2, and 10 mM HEPES
pH 7.4). The mixture was shaken for 10 min at room tem-
perature and diluted in cell culture fusion medium to
defined concentrations immediately before use. Cultures
were routinely treated with 20 μM pervanadate. Src-class
kinase inhibitor PP2 [4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine] (Calbiochem) was
diluted into cell culture medium to a final concentration
of 10 μM [14,54].
Antibodies
Antibodies against phosphotyrosine (PY20, 4G10); the
AChR β subunit (mAb35); the conserved C-terminus of
Src, Fyn, and Yes (src-CT); MuSK; rapsyn; and β-dystrogly-
can were all used as previously described [17,55,56].
Human anti-MuSK serum was obtained from Dr. Angela
Vincent, Oxford, UK. It originates from myasthenia gravis
patients who had high concentrations of anti-MuSK anti-
bodies in their bloodstream. Experiments for Figure 3
were carried out with this serum and also with rabbit anti-
MuSK antibodies [50], producing identical results. SHP-2
antibody (sc-7384; Santa Cruz Biotechnology Inc., CA,
USA); Alexa Fluor® 488 anti-mouse and Alexa Fluor® 546
anti-rabbit (Molecular Probes, Eugene, OR, USA); rabbit
polyclonal c-Myc antibody (sc-789; Santa Cruz Biotech-
nology Inc., CA, USA); and mouse monoclonal Flag M2
antibody (F3165; Sigma, Switzerland) were used as indi-
cated by the suppliers.
Assay for stability of AChR clusters
To study the effect of pervanadate on the stability of agrin-
induced AChR clusters, C2C12 myotubes were treated
with agrin (1 nM) for 6–8 hours to induce clustering, and
were subsequently washed twice with fusion medium and
maintained in fusion medium lacking agrin for 16 h, in
the presence or absence of pervanadate (20 μM). The
washing procedure was shown to be efficient in removing
the vast majority of agrin from cells, one reason presuma-
bly being the lack of the laminin-binding site in C-Ag12,4,8
[7]. In controls, C2C12 myotubes were treated with agrin
for 6–8 h followed by withdrawal of agrin for 16 h, myo-
tubes were simply treated with agrin for 6–8 h, or cultures
were left untreated. In src-/-;fyn-/- and corresponding wild-
type cells, following a 16 h treatment with agrin, cultures
were washed twice with DM fusion medium and main-
tained in fusion medium for 5 hours, in the presence or
absence of pervanadate. In controls, src-/-;fyn-/- and corre-
sponding wild-type cells were incubated with agrin for 16
h followed by withdrawal for 5 h, incubated with agrin for
16 h, or cultures were left untreated.
To study the requirement for both SFKs and PTPs for the
stability of agrin-induced AChR clusters, cultures were
treated with agrin for 6–8 hours. Src-class kinase inhibitor
PP2 (10 μM) was added to cultures during the last 2 hours
of agrin treatment [14,54]. Cultures were then washed
twice with fusion medium followed by a 16 h incubation
in fusion medium including PP2, or PP2 and pervanad-
ate.
AChR clustering assay and quantification of clusters
To study the effects of inhibitors and of SHP-2 shRNA on
AChR cluster formation or stability, AChR clusters were
visualized by incubating myotube cultures grown in 3.5
cm dishes with 100 nM tetramethylrhodamine-conju-BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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gated  α-bungarotoxin (α-BTX) (Molecular Probes) in
fusion medium for 1 hour at 37°C followed by fixation in
3% paraformaldehyde (PFA) in potassium phosphate
buffer containing 4% sucrose for 15 minutes at room tem-
perature, or in methanol for 7 minutes at -20°C [55].
Myotubes were examined at 400× magnification in both
rhodamine and fluorescein channels with a fluorescence
microscope (Axioskop II; Zeiss). Representative pictures
(1344 × 1024 pixels) were taken and processed with a
cooled digital camera (Orcacam; Hamamatsu) and Sim-
plePCI software run on a Dell Dimension 8300 personal
computer. The exposure times for individual channels
were kept constant in all experiments.
AChR clusters were quantified using the NIH ImageJ 1.34
software. Images were opened in ImageJ; the scale was set
to 3.8 pixels/μm for pictures taken at 400×, and to 1.9 pix-
els/μm for pictures taken at 200×. The threshold levels
were set to 150–255, depending on the general back-
ground. Particles were analyzed, with the minimum parti-
cle size defined at 100 pixels. Data extracted from each
picture included minimum and maximum particle size,
mean particle size, mean particle area and number of par-
ticles. Particles >100 pixels approximated very closely to
what would be considered as a cluster >10 μm length as
judged by eye, and were thus taken as representative of a
single AChR cluster. AChR clusters were quantified from
approximately 15 random fields per experiment, and the
mean ± SEM number of clusters per field was determined.
We did several trial quantitations by both this automated
method and by eye, and the outcome was very similar –
hence our method reports very closely what can be seen by
eye (A. A. Camilleri and C. Fuhrer, unpublished observa-
tions).
Immunoprecipitations and immunoblot analysis
For immunoprecipitation of MuSK, cell lysates from cells
grown on 10 cm plates were prepared as previously
described [7,50], and MuSK precipitated using human
anti-MuSK sera or rabbit MuSK antibodies, followed by
protein A or G sepharose beads (GE Healthcare, Uppsala,
Sweden), as previously described [7,50]. Following
immunoprecipitations, all samples were loaded on
sodium dodecyl sulfate (SDS)-polyacrylamide gels and
probed using a mixture of phosphotyrosine antibodies
4G10 and PY20, and subsequently anti-MuSK or anti-
SHP-2 antibodies (details above). Quantitations of
immunoblots were done by scanning exposed films con-
taining grey, nonsaturated signals with a computerized
densitometer (HP Scanjet 5530) and using the NIH
ImageJ 1.34 software. Experiments were repeated seven
times, to obtain consistent results.
To analyze the effects of SHP-2 knockdown on the endog-
enous levels of SHP-2 and several other postsynaptic pro-
teins, mature transfected myotubes were lysed, and equal
amounts of proteins were loaded onto SDS gels. Follow-
ing transfer to nitrocellulose paper, postsynaptic proteins
were probed using specific antibodies against rapsyn, β-
DG, MuSK, SHP-2, AChR β subunit and Src-CT.
Expression constructs and shRNA
Myc-tagged wild-type MuSK expression construct, MuSK-
myc  (pMuSK_myc), was a gift of Prof. H.R. Brenner
(Department of Physiology, University of Basel, Switzer-
land) [57]. Wild-type SHP-2 (obtained from Dr. J.L. Bixby
(University of Miami School of Medicine, Miami, USA))
[58] was subcloned into Bam/Not  of  pcDNAI-Flag  to
obtain a SHP-2-Flag (pcDNAI-SHP-2-Flag) construct. The
constructs were transfected into COS cells using Fugene6
(Roche, Basel, Switzerland) as described below.
pSUPER.neo+gfp  vector (pSUPER) was purchased from
OligoEngine (Seattle, USA). A shRNA (short-hairpin
RNA) construct against murine SHP-2 (NCBI Accession
number NM_011202) was generated by cloning the target
sequence (5'-gaatacggggtcatgcgtgtt-3') into the BglII/XhoI
sites of the pSUPER vector (adapted from [27]) according
to the manufacturer's recommendations.
Transfections
Transfections of constructs into C2C12 and COS cells
were carried out using Fugene6 transfection reagent
(Roche, Basel, Switzerland) according to the manufac-
turer's recommendations. Optimal transfection condi-
tions were established by transfecting C2C12 myoblasts at
70–90% confluence. Two days later cells were induced to
fuse by switching to fusion medium for 2 days. Trans-
fected cells were observed by the expression of green fluo-
rescence protein (GFP). Transfection efficiency on the
myoblast stage was at 40–50%, and at the myotube stage
(following fusion) was estimated at 80–100%. For co-
transfection of COS cells with MuSK-myc and SHP-2-Flag
constructs, equal quantities of DNA were transfected.
125I-α-bungarotoxin binding assay
To measure the surface level of AChRs following SHP-2
knockdown by shRNA, myotube cultures grown in 3.5 cm
plates were incubated with 125I-α-BTX (Amersham Bio-
sciences, Arlington Heights, IL) for 1 hour at 37°C. Cul-
tures were washed twice with cold PBS supplemented with
1 mM Na orthovanadate and 50 mM NaF and lysed at 4°C
in 1 ml lysis buffer [50] for 15 minutes. Cell lysate aliq-
uots were taken for protein determination assays. Radio-
activity from surface AChR-bound 125I-α-BTX was counted
in an LKB Wallac 1282 CompuGamma counter (2 min
counting mode). Non-specific binding was determined
using 1 μM unlabelled α-BTX (1 hour pre-incubation and
during radioactive labeling) [54]. Radioactive signals were
robust (30000–100000 cpm), and the non-specific back-BMC Neuroscience 2007, 8:46 http://www.biomedcentral.com/1471-2202/8/46
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ground was low (5–10%). Counts were normalized for
the total protein content for each sample. AChR surface
levels following SHP-2 knockdown by shRNA were plot-
ted as percentages of pSUPER transfected controls.
In vivo electroporation of soleus muscles, whole-mount 
preparation, and immunohistochemistry
Targeting of SHP-2 in vivo was achieved by electroporating
the shRNA construct pSUPER.shSHP2 (2 or 4 μg/μl final
concentration) into the soleus muscle of mice, together
with green fluorescent protein (GFP) containing a nuclear
localization signal (NLS-GFP; 2 μg/μl). In control mice,
soleus muscles were electroporated with pSUPER vector
construct (2 or 4 μg/μl) together with NLS-GFP (2 μg/μl).
DNA constructs were pre-mixed and injected into the
soleus muscle of adult C57BL/6 mice (8–11 weeks of age).
After closing the wound, electrodes were mounted against
the leg, and electroporation was performed as described
previously [8] using an ECM 830 electroporation system
(BTX, Holliston, MA). The procedure for the electropora-
tion, dissection, fixation, and whole mount preparation
of the muscle fibers was carried out as detailed previously
[8,11]. Muscle fibers were stained with polyclonal anti-
neurofilament and anti-synaptophysin antibodies fol-
lowed by Cy5-conjugated goat anti-rabbit antibodies to
visualize the nerve, as well as with rhodamine-α-BTX to
detect AChRs, as previously described [8,11].
Confocal imaging, image processing and quantitations
Confocal microscopy was used to analyze the mounted,
fixed and stained muscle fibers. A Leica SP5 laser scanning
microscope (Leica Microsystems, Wetzlar, Germany) run-
ning on a Hewlett-Packard Workstation xw6400, and a
20× oil-immersion lens, with settings specific for EGFP
(green), rhodamine (red) and Cy5 (blue), were used. The
three channels were detected sequentially, adjusting the
laser power and detection windows individually for each
channel, so as to exclude bleed-through. Confocal stacks
were generated, and image processing, analysis, and three-
dimensional reconstructions of confocal stacks was car-
ried out using Imaris 5.0.1 software (Bitplane, Zurich,
Switzerland) as previously described [8,11]. Assessment
of NMJ disassembly and quantitation were done as
detailed before [11]. Briefly, only endplates having GFP-
positive synapse-associated nuclei were taken into consid-
eration for quantitation, to make sure that NMJs corre-
sponded to electroporated myofibers. Intact endplates
were large, compact, pretzel-shaped structures of labelled
AChRs, appearing brightly stained and continuous along
their contours. Endplates were considered disassembled
when the typical pretzel shape was no longer present, or
endplates were crumpled and broken up into fragments.
Quantitation of the number of intact or disassembled
NMJs was done for each vector. A total of 25 endplates
from three mice for the control pSUPER vector, and 15
endplates from five mice for the pSUPER.shSHP2 vector
were analyzed.
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